Dr. Harald Poth, Marco Winzer and Prof. Dr. Pascal Fries new members of CorTecs Advisory Board
Following the conclusion of a new round of investments last fall, CorTec is now expanding the expertise in the two advisory boards of the medical technology company. Dr. Harald Poth from LBBW Venture Capital GmbH joins the company’s Advisory Board together with Marco Winzer from High-Tech Gründerfonds (HTGF), who is replacing Mr. Bernhard Meder. Prof. Dr. Pascal Fries from the Ernst Strüngmann Institute for Neuroscience was appointed to the Scientific-Technical Advisory Board of CorTec.
For the managing directors of CorTec, Dr. Jörn Rickert and Dr. Martin Schüttler, the expansion of both advisory boards represents a perfect complement to the two committees. “The participation of the Strüngmann family in our company has already brought us an important increase in industry expertise in the life science sector. The addition of new highly experienced members to our advisory boards strengthens us as a company on our path to innovation in neurotherapy,” commented Dr. Martin Schüttler. “With their many years of expertise in setting up and expanding young companies in our industry, Dr. Harald Poth and Marco Winzer combine valuable business and expertise. The fact that we have also been able to attract Prof. Dr. Pascal Fries, a neuroscientist of the highest international repute, completes the competence of our Scientific and Technical Advisory Board in an extremely profitable way,” adds Dr. Jörn Rickert.
Dr. Harald Poth is a member of the management of LBBW Venture Capital GmbH in Stuttgart. Poth, who holds a doctorate in biology, leads the life science team of the investment company, which focuses on innovative technologies. Marco Winzer has been involved in setting up HTGF from the very beginning and has since then supported many companies. The economist heads the life sciences & chemistry team of the successful seed financier. Prof. Dr. Pascal Fries is one of the most important neuroscientists worldwide. In addition to a professorship at the Radboud University in Nijmegen, the Netherlands, he is a Scientific Member of the Max Planck Society and Director at the Ernst Strüngmann Institute in Frankfurt.
“As LBBW Venture, we are pleased to be able to support one of the world’s most innovative neurotechnology companies with our expertise together with the new investor Santo Ventures,” said Dr. Harald Poth. “I am very much looking forward to accompanying CorTec on its growth course and the upcoming internationalization”, adds Marco Winzer.
“I am very much looking forward to the cooperation with the CorTec team. I see electrophysiological interactions with our nervous system as a very important possibility for temporally and spatially precise as well as demand-controlled therapies in real time,” explains Prof. Dr. Pascal Fries. “This therapeutic potential is far from being exhausted, and CorTec is excellently positioned internationally with its technologies, its strong connection to the University of Freiburg and its vision.
With the addition of the new advisory board, CorTec bids farewell to its long-standing member Bernhard Meder from the company’s advisory board. “CorTec GmbH has supplemented its advisory board with Dr. Poth and Winzer – by a corresponding resolution of the shareholders’ meeting. At the same time, Mr. Meder has resigned from the Advisory Board of CorTec due to heavy professional demands in his own group of companies. We thank Mr. Meder for his excellent support in the past years. Of course, Mr. Meder will continue to be a shareholder of CorTec GmbH,” explains the Chairman of the Advisory Board Prof. Dr. Klaus Mangold.
In addition to Prof. Dr. Mangold, the long-time CTO of Otto Bock HealthCare GmbH, Dr. Hans Dietl, will remain on the company’s advisory board. Next to the new member, the Scientific-Technical Advisory Board will continue to be comprised of Prof. Dr. Volker A. Coenen (Medical Director of the Department of Stereotactic and Functional Neurosurgery in the Clinic for Neurosurgery at the University Hospital Freiburg), Alexander Mayr (Head of Implant Production, Med-El, Innsbruck), Prof. Dr. Thomas Stieglitz (Professor of Biomedical Microtechnology, University of Freiburg) and Prof. Dr. Ulf Ziemann (Medical Director of the Neurological Clinic, University Hospital Tübingen).
With the support of the extended expertise in both advisory boards, CorTec now aims for further growth and an early first human application of the Brain Interchange® System for closed-loop interaction with the human brain, which enables innovative personalized neurotherapies.